Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): a population-based cohort study
- PMID: 24556022
- DOI: 10.1016/S0140-6736(13)62564-7
Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): a population-based cohort study
Abstract
Background: The pattern of endocrine disorders in long-term survivors of childhood cancer has not been investigated comprehensively. Here, we aimed to assess the lifetime risk of these disorders in Nordic survivors of childhood cancer.
Methods: From the national cancer registries of Denmark, Finland, Iceland, Norway, and Sweden, we identified 31,723 1-year survivors of childhood cancer, notified since the start of registration in the 1940s and 1950s. From the national population registries, we randomly selected a comparison cohort of people matched by age, sex, and country. Study participants were linked to the national hospital registries, and observed numbers of first-time hospital contacts for endocrine disorders in survivors of childhood cancer were compared with the expected numbers derived from the population comparison cohort. We calculated the absolute excess risks attributable to status as a childhood cancer survivor and standardised hospitalisation rate ratios (SHRRs).
Findings: Of the childhood cancer survivors, 3292 had contact with a hospital for an endocrine disorder, yielding a SHRR of 4·8 (95% CI 4·6-5·0); the highest risks were in survivors of leukaemia (SHRR 7·3 [95% CI 6·7-7·9]), CNS tumours (6·6 [6·2-7·0]), and Hodgkin's lymphoma (6·2 [5·6-7·0]). The absolute excess risk for endocrine disorders was roughly 1000 per 100,000 person-years before 20 years of age, and 400 per 100,000 person-years during the remaining lifetime. For children with cancer diagnosed at 5-9 years of age, the cumulative risk for endocrine disorders was highest, and reached 43% at the age of 60 years. Diagnoses of pituitary hypofunction (SHRR 88·0), hypothyroidism (9·9), and testicular and ovarian dysfunction (42·5 and 4·7, respectively) together constituted 61% (655 of 1078) of all excess disease-induced and treatment-induced endocrine disorders in survivors of childhood cancer.
Interpretation: A cumulative risk for endocrine disorders at 60 years of age of above 40% in survivors of childhood cancer emphasises the importance of minimisation of damaging treatment, intensification of secondary prevention, and targeting of survivor follow-up throughout life. Since most long-term childhood cancer survivors are not followed in a specialised late-effect clinic, they are a growing challenge for the primary care physician and medical specialists working outside the late-effect area.
Funding: The Danish Council for Strategic Research.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Comment in
-
Childhood cancer, endocrine disorders, and cohort studies.Lancet. 2014 Jun 7;383(9933):1950-2. doi: 10.1016/S0140-6736(14)60114-8. Epub 2014 Feb 18. Lancet. 2014. PMID: 24556021 Free PMC article. No abstract available.
-
Epidemiology. Endocrine disorders in adult survivors of childhood cancer.Nat Rev Endocrinol. 2014 Jun;10(6):320-1. doi: 10.1038/nrendo.2014.50. Epub 2014 Apr 8. Nat Rev Endocrinol. 2014. PMID: 24709656
Similar articles
-
Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood cancer survivors.PLoS Med. 2017 May 9;14(5):e1002296. doi: 10.1371/journal.pmed.1002296. eCollection 2017 May. PLoS Med. 2017. PMID: 28486495 Free PMC article.
-
Adult life after childhood cancer in Scandinavia: diabetes mellitus following treatment for cancer in childhood.Eur J Cancer. 2014 Apr;50(6):1169-75. doi: 10.1016/j.ejca.2014.01.014. Epub 2014 Feb 4. Eur J Cancer. 2014. PMID: 24507548
-
Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries.J Natl Cancer Inst. 2009 Jun 3;101(11):806-13. doi: 10.1093/jnci/djp104. Epub 2009 May 26. J Natl Cancer Inst. 2009. PMID: 19470947
-
Survivorship: adult cancer survivors.Prim Care. 2009 Dec;36(4):721-41. doi: 10.1016/j.pop.2009.08.001. Prim Care. 2009. PMID: 19913184 Review.
-
Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab. 2018 Aug 1;103(8):2761-2784. doi: 10.1210/jc.2018-01175. J Clin Endocrinol Metab. 2018. PMID: 29982476 Review.
Cited by
-
Anti-Müllerian hormone and fertility in women after childhood cancer treatment: Association with current infertility risk classifications.PLoS One. 2024 Aug 12;19(8):e0308827. doi: 10.1371/journal.pone.0308827. eCollection 2024. PLoS One. 2024. PMID: 39133666 Free PMC article.
-
Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study.Br J Cancer. 2024 Apr;130(7):1166-1175. doi: 10.1038/s41416-024-02594-x. Epub 2024 Feb 8. Br J Cancer. 2024. PMID: 38332179
-
Efficacy and safety of endoscopic retrograde cholangiopancreatography in recurrent pancreatitis of pediatric asparaginase-associated pancreatitis.World J Gastrointest Endosc. 2023 Oct 16;15(10):614-622. doi: 10.4253/wjge.v15.i10.614. World J Gastrointest Endosc. 2023. PMID: 37900113 Free PMC article.
-
Expert Opinion on the Management of Growth Hormone Deficiency in Brain Tumor Survivors: Results From an Italian Survey.Front Endocrinol (Lausanne). 2022 Jul 14;13:920482. doi: 10.3389/fendo.2022.920482. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35909559 Free PMC article.
-
Multimorbidity patterns and risk of hospitalisation in children: A population cohort study of 3.6 million children in England, with illustrative examples from childhood cancer survivors.Lancet Reg Health Eur. 2022 Jun 30;20:100433. doi: 10.1016/j.lanepe.2022.100433. eCollection 2022 Sep. Lancet Reg Health Eur. 2022. PMID: 35799614 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
